Viral Inactivation Global Market Report 2024

The viral inactivation market has grown strongly in recent years. It will grow from $4.54 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The increase observed in the historical period can be credited to the growth of global air traffic, advancements in navigation capabilities, the expansion of commercial aviation, cost savings for airlines, improved flight safety, and a decrease in pilot workload.

The viral inactivation market is expected to see rapid growth in the next few years. It will grow to $7.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in the forecast period can be ascribed to the development of autonomous flight, advancements in next-generation aircraft designs, initiatives toward sustainable aviation, the rise of urban air mobility (UAM), and an increasing demand for aircraft. Key trends in the forecast period encompass the integration of advanced avionics, the adoption of artificial intelligence, innovations in human-machine interface (HMI), retrofitting existing aircraft, and the integration of the global navigation satellite system (GNSS).

The anticipated rise in the viral inactivation market is driven by the increasing occurrences of various infectious diseases. These diseases, which can spread through contaminated foods, beverages, and various pathogens such as viruses, bacteria, fungi, and parasites, underscore the significance of viral inactivation in human disease-control initiatives. The utilization of physical and chemical disinfectants for viral inactivation plays a crucial role in preventing the transmission of contagious viral infections. A notable example is the 'Annual Epidemiological Report for 2021,' published by the European Centre for Disease Prevention and Control, a Sweden-based European Government Health Agency, which reported an increase in hepatitis C cases in Germany from 4,536 cases and 5.5 rates per 100,000 population in 2020 to 4,718 cases and 5.7 rates in 2021. Consequently, the escalating instances of infectious diseases contribute to the growth of the viral inactivation market.

The surge in the prevalence of cancer cases is poised to drive the growth of the viral inactivation market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells leading to tumor formation, necessitates treatments involving biological products. Ensuring the safety of these products through viral inactivation becomes paramount in preventing potential infections among patients undergoing cancer treatments. According to the American Cancer Society Inc., a US-based non-profit health group, the projected number of new cancer cases in the US is expected to increase from over 1,918,030 in 2022 to 1,958,310 in 2023. This escalation in cancer cases underscores the growing importance of viral inactivation in the market.

A prominent trend gaining traction in the viral inactivation market is the increased adoption of technologically advanced processes. Companies within this market are incorporating state-of-the-art technologies to maintain their competitive positions. For example, in March 2022, WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, a China-based biopharmaceutical company, introduced the Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology. This cutting-edge approach facilitates the approval of new therapies by concurrently conducting all assay formulation, biosafety, viral clearance, product release, and testing in-house. TESSA Technology represents an innovative method for producing adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade without the need for transfection.

Major players in the viral inactivation market are focusing on the development of groundbreaking products, such as non-hazardous viral inactivation mediums, to gain a competitive edge. Non-hazardous viral inactivation mediums are formulations designed to inactivate viruses in laboratory or clinical settings without posing risks or hazards to individuals handling the samples. Thermo Fisher Scientific Inc., a US-based biotechnology company, exemplified this approach in March 2022 with the launch of the InhibiSURE Viral Inactivation Medium. This breakthrough formulation is specifically designed for the safe collection and transport of the SARS-CoV-2 virus, ensuring rapid inactivation and stabilization of viral RNA at ambient temperature. The medium eliminates potential hazards associated with traditional inactivation media, enhancing laboratory safety and contributing to a secure and efficient sample collection and transport process.

In June 2022, Asahi Kasei Medical, a Japan-based healthcare company specializing in chemical manufacturing, acquired Bionova Scientific for an undisclosed amount. This acquisition provides Asahi Kasei access to Bionova's 36,000-square-foot production facility equipped with two 2,000-litre mammalian cell culture trains. The facility has the capacity to produce various monoclonal antibodies and other recombinant proteins. Post-acquisition, Asahi Kasei aims to leverage its existing businesses in bioprocess supplies, tools, biosafety testing services, and the biologics CDMO division of Bionova Scientific. Bionova Scientific, a US-based company, is engaged in the cGMP manufacturing of biologics and downstream purification processes for viral inactivation and viral filtration.

Major companies operating in the viral inactivation market report are Merck & Co. Inc., PARKER HANNIFIN CORP., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., SCI Automation Pte. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited.

North America was the largest region in the viral inactivation market in 2023. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral inactivation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary outcomes of viral inactivation are kits and reagents, systems, and services. The solvent detergent method is a technique that damages the lipid membrane of encapsulated viruses, leading to their inactivation. This method is frequently employed in plasma processing to safely deactivate all lipid-enveloped viruses. Viral inactivation encompasses various methods, including the solvent detergent method, pH adjustment method, pasteurization, and others. These methods are applied in vaccines and therapeutics, tissues and tissue products, blood and blood products, and various other applications. End-users of viral inactivation include pharmaceutical and biotechnology companies, contract research organizations, blood banks, hospitals, academic research institutes, and other entities.

The viral inactivation market research report provides viral inactivation market statistics, including viral inactivation industry global market size, regional shares, competitors with a viral inactivation market share, detailed viral inactivation market segments, market trends and opportunities, and any further data you may need to thrive in the viral inactivation industry. This viral inactivation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral inactivation market includes revenues earned by chemical viral inactivation and radiation viral inactivation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.